PHARMA EVIDENCE ApS: Financial statements 2025
CVR: 34586519
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
PHARMA EVIDENCE ApS (CVR 34586519) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 64,007 and a net result of DKK 62,147 compared with DKK -179,749 the year before. Equity in the 2025 report amounted to DKK 134,401. The solvency ratio was 47.7%.
- Gross Profit
- DKK 64,007
- Profit/Loss
- DKK 62,147
- Equity
- DKK 134,401
- Total Assets
- DKK 281,992
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 64 t. | 62 t. | 134 t. | 0 |
| 2024 | - | -158 t. | -180 t. | 72 t. | 0 |
| 2023 | - | -428 t. | -796 t. | 252 t. | 1 |
| 2022 | - | 552 t. | 197 t. | 1 mio. | 1 |
| 2021 | - | 196 t. | -442 t. | 851 t. | 1 |
Official annual report
How creditworthy is PHARMA EVIDENCE ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
PHARMA EVIDENCE ApS has published its annual report for 2024. Gross profit came to DKK -157,709, and the net result was DKK -179,749.
About PHARMA EVIDENCE ApS
PHARMA EVIDENCE ApS is a Danish company of the type Anpartsselskab based in Farum, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Tove Holm-Larsen. The company is owned by HB World Holding ApS. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK 64,007 and a net result of DKK 62,147 compared with DKK -179,749 the year before. Equity in the 2025 report amounted to DKK 134,401.